Volcani Center has announced “significant breakthroughs” in CTCL skin cancer cannabis treatment in co-operation with MedC Biopharma Corporation of Canada.
The company is preparing patents for the treatment of CTCL (Cutaneous T cell lymphoma), a class of non-Hodgkin lymphoma, a cancer of the immune system.
“CTCL is classified by the FDA as an Orphan Disease, and as such products developed for this disease have the potential to achieve orphan status designation which can accelerate licensing and create a seven-year exclusivity window,” Volcani Center stated in a release.
“Headed by Professor Hinanit Koltai, the patents are based on a unique formulation of active compounds selectively extracted from the cannabis plant, which have highly cytotoxic activity against malignant T-cell lines,” the company adds.
Clinical trials for a cannabis-based medication developed specifically for CTCL are planned to begin in early 2019.
“We are delighted that our collaborative efforts with MedC will provide them with the IP that will help pave the way in treating CTCL,” said Professor Hinanit Koltai, at Volcani Center.
Avi Drori, Chairman of MedC Corp (Canada), said the company is pleased investments in the development of cannabis-based medication for CTCL has “matured into breakthrough discoveries and resulting patents.”
“We look forward to commencing clinical trials, so we can finally bring hope to patients world-wide seeking a cure for this terrible disease,” added Drori.
Further development and distribution are via an “exclusive global licensing agreement signed by the ARO via Kidum with cannabis pharmaceutical company MedC Biopharma Corporation of Canada, which has invested in the development of CTCL treatments at ARO to secure the exclusive global license for the CTCL patents, a significant milestone in its efforts to further its aims to become the largest repository of IP in the Pharma Cannabinoids arena.”
Located at the Volcani Center, near Tel-Aviv, ARO is the “country’s leading cannabis research powerhouse with a repository of IP developed by a team of scientists, whose research has identified multiple effective compositions of cannabinoids and terpenes in the past years,” according to a release.
MedC’s investors include one of Canada’s leading LP & pharmaceutical cannabis company, AgMedica Bioscience. MedC has also forged a partnership with Nextage Innovation Israel, as MedC’s exclusive partner for the development of cannabis-based Rx products including for the development of the CTCL treatments.